Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001001029 | SCV001158139 | likely benign | Noonan syndrome 9 | 2023-08-23 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193055 | SCV001361619 | benign | not specified | 2019-08-24 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001001029 | SCV001722707 | benign | Noonan syndrome 9 | 2024-01-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002434391 | SCV002745018 | likely benign | Cardiovascular phenotype | 2022-04-11 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Genome- |
RCV001001029 | SCV002763027 | benign | Noonan syndrome 9 | criteria provided, single submitter | clinical testing | ||
Ce |
RCV003389855 | SCV004134080 | likely benign | not provided | 2023-03-01 | criteria provided, single submitter | clinical testing | SOS2: BP4, BP7 |